Indiscriminate use of Convalescent Plasma therapy not advisable for Covid-19 treatment: ICMR

Indian Council of Medical Research (ICMR) has advised that indiscriminate use of Convalescent Plasma therapy is not advisable for the treatment of the Covid-19 cases.

ICMR conducted an open label phase II multicentre randomised controlled trial in India across 39 public and private hospitals on use of convalescent plasma in the management of cases with moderate COVID-19 disease.

In the trial, it has been concluded that Convalescent Plasma therapy did not lead to reduction in progression to severe Covid-19 or all cause mortality in the group that received Convalescent Plasma therapy as compared to the group that did not receive the therapy.


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies